Replies to post #225327 on Biotech Values

[DewDiligence]

Bizarre: ABUS +40% on mere clearance to start a phase-1 trial for AB-729.

[DewDiligence]

ABUS reports phase-1b HBV data for AB-506:

https://finance.yahoo.com/news/arbutus-announces-preliminary-phase-1a-200500198.html

Mean HBV DNA and HBV RNA decreases at Day 28 (end of treatment) ranged from -2.0 log (160mg dose) to -2.8 log (400mg dose) and -2.4 log (for both doses), respectively…

These log-reduction-in viral-load numbers seem a little low for 28 days of treatment.

ABUS’ AB-506 works by the same MoA as ENTA’s EDP-514 (#msg-149794330). ASMB has one too (#msg-148672065).